Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline. CEO Vas Narasimhan said ...

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...

Novartis' drug segment is poised for steady cash flows driven by new pipeline products and existing drugs. Novartis' strategy to focus largely in areas of unmet medical need should strengthen the ...

Amid renewed threats of import tariffs on pharmaceuticals from the Trump administration, Novartis plans to spend $23 billion over the next five years to expand its manufacturing, research and ...

Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities. The move comes after President Trump earlier this week threatened "major" tariffs on ...

Steffen Lang, president, operations, executive committee member, Novartis, shares strategic insights on how pharma supply ...